Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Robert M. Rifkin, Stephen J. Noga et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 16